Table 1 Descriptive statistics of diffuse large B-cell lymphoma with or without diabetes type 1/2 treated with rituximab-doxorubicin based chemotherapy at Roswell Park Comprehensive Cancer Center
| Â | All Patients | Non-Diabetic | Diabetic No Metformin | Diabetic Metformin |
|---|---|---|---|---|
Number (%) | 264 | 215 (81.4%) | 21/49 (8.0%) | 28/49 (10.6%) |
Median Age | 60 | 58 | 73 | 63.5 |
Sex | ||||
F/M | 92/172 (34.8%/65.2%) | 73/142 (34.0%/66%) | 6/15 (28.6%/71.4%) | 13/15 (46.4%/53.6) |
Subtype | ||||
GCB | 70 (26.5%) | 55 (25.6%) | 6 (28.6%) | 9 (32.1%) |
Non-GCB | 94 (35.6%) | 76 (35.3%) | 8 (38.1%) | 10 (35.7%) |
UNK | 100 (37.9%) | 84 (39.1%) | 7 (33.3%) | 9 (32.1%) |
Stage | ||||
I-II/III-IV | 94/167 (36.0%/64.0%) | 79/134 (37.1%/62.9%) | 7/14 (33.3%/66.6%) | 8/20 (28.6%/71.4%) |
IPI Risk Category | ||||
High | 19 (7.2%) | 16 (7.4%) | 1 (4.8%) | 2 (7.1%) |
High-Int | 58 (22.0%) | 41 (19.1%) | 8 (38.1%) | 9 (32.1%) |
Low-Int | 97 (36.7%) | 78 (36.3%) | 8 (38.1%) | 11 (39.3%) |
Low | 90 (34.1%) | 80 (37.2%) | 4 (19.0%) | 6 (21.4%) |
Treatment Type | ||||
R-CHOP | 231 (87.5%) | 185 (86.0%) | 19 (90.5%) | 27 (96.4%) |
R-CHOP-Doxil | 8 (3.0%) | 6 (2.8%) | 2 (9.5%) | 0 (0%) |
R-CHOP-MTX | 2 (0.8%) | 2 (0.9%) | 0 (0%) | 0 (0%) |
R-EPOCH | 23 (8.7%) | 22 (10.2%) | 0 (0%) | 1 (3.6%) |
Radiation Not treated vs. Treated | 182/78 (70.0%/30.0%) | 145/67 (68.4%/31.6%) | 18/2 (90.0%/10.0%) | 19/9 (67.9%/32.1%) |